Enhancing Financial Leadership: Navidea Biopharmaceuticals Hires Craig A. Dais as CFO

DUBLIN, Ohio--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) has announced the appointment of Craig A. Dais, CPA as the company's Chief Financial Officer (CFO). In this role, Dais will provide financial expertise and oversight to drive the company's growth strategies and advance its innovative technology to market.

Financial Expertise, Leadership, and Oversight

With over 30 years of experience as a financial executive and Certified Public Accountant, Craig A. Dais brings valuable expertise in accounting, financial modeling, capital development, and growth-oriented leadership. As the new CFO, Dais will oversee all financial aspects of Navidea, including the preparation of financial statements, reporting and analysis, cash flow management, and the development of expert teams responsible for financial activities.

Navidea's Chief Medical Officer, Michael Blue, recognizes Dais's ability to see both the details and the big picture. He describes Dais as a self-motivated leader with a track record of developing strong teams that provide insights, reporting, and financial acumen. Blue believes that Dais's financial leadership will contribute to bringing Navidea's transformative technology and assets to the forefront.

Dais's Career Accomplishments

Throughout his career, Craig A. Dais has held various roles of increasing responsibility, including CFO at Colorado Pain Care, LLC, Fractional CFO at Ascent CFO Solutions, CFO at Duffy Crane & Hauling, and Vice President of Finance at Pendum LLC. He has also served in leadership positions in both public and private organizations, demonstrating his ability to navigate diverse financial landscapes. Dais began his finance career at KPMG Peat Marwick. He holds a Bachelor of Science in Accounting, with a Minor in Business, from Metropolitan State University of Denver, and is a Certified Public Accountant.

Dais's Excitement for the Future

Expressing his enthusiasm for joining Navidea as CFO, Craig A. Dais states that his experience and career have led him to this role. He believes in Navidea's transformative technology and its potential to improve lives worldwide. Dais's goal is to leverage his expertise to make Navidea's vision a reality.

About Navidea

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. The company is developing targeted products based on its Manocept platform, which aims to enhance patient care by identifying disease sites and pathways, enabling better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform specifically targets the CD206 mannose receptor expressed on activated macrophages. Tc99m tilmanocept is the first product developed and commercialized by Navidea based on this platform. The company's strategy includes delivering growth and shareholder return by bringing novel products to market and advancing its pipeline through global partnering and commercialization efforts.

About G2G Ventures

G2G Ventures is a private equity firm based in Colorado, specializing in empowering organizations to reach their full potential through investment and consulting services. The firm creates long-term partnerships with trusted investors and established businesses, offering bespoke capital solutions such as private equity investment, venture capital participation, and mezzanine debt options. G2G Ventures also provides consulting services to help businesses clarify strategic goals, evolve financial processes, and enhance operational effectiveness.

Forward-Looking Statements

This press release contains forward-looking statements regarding Navidea Biopharmaceuticals, Inc. These statements are based on current expectations and projections about future events and financial trends. They include expectations about pending litigation and other matters. However, these forward-looking statements are subject to risks, uncertainties, and assumptions, such as the company's history of operating losses and uncertainty of future profitability, timing and cost of obtaining regulatory approvals, and advances in technology. Investors are urged to review the company's SEC filings for a comprehensive understanding of the risk factors involved.

Conclusion

The appointment of Craig A. Dais as CFO of Navidea Biopharmaceuticals marks a significant step toward enhancing the company's financial expertise and leadership. Dais's extensive experience and expertise will ensure effective financial management, enabling Navidea to drive its growth strategies and bring its innovative technology to the forefront. With Dais's guidance, Navidea is poised to make a positive impact in the field of precision immunodiagnostic agents and immunotherapeutics.